Fred Alger Management LLC Cuts Stock Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Fred Alger Management LLC lessened its holdings in Autolus Therapeutics plc (NASDAQ:AUTL) by 99.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,262 shares of the company’s stock after selling 1,186,614 shares during the period. Fred Alger Management LLC’s holdings in Autolus Therapeutics were worth $36,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in AUTL. Perceptive Advisors LLC purchased a new stake in Autolus Therapeutics during the 4th quarter worth $11,793,000. Price T Rowe Associates Inc. MD increased its stake in Autolus Therapeutics by 82.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares during the period. BNP Paribas Financial Markets increased its stake in Autolus Therapeutics by 2,603.8% during the 1st quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock worth $736,000 after buying an additional 111,131 shares during the period. Bank of New York Mellon Corp increased its stake in Autolus Therapeutics by 74.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock worth $8,810,000 after buying an additional 1,080,897 shares during the period. Finally, Great Point Partners LLC increased its stake in Autolus Therapeutics by 195.0% during the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after buying an additional 2,275,000 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Price Performance

Shares of AUTL stock opened at $3.63 on Friday. The firm has a market cap of $965.71 million, a P/E ratio of -3.03 and a beta of 2.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.55 and a quick ratio of 18.55. Autolus Therapeutics plc has a 1-year low of $2.01 and a 1-year high of $7.45. The firm has a fifty day moving average of $4.00 and a two-hundred day moving average of $4.33.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.03). As a group, research analysts anticipate that Autolus Therapeutics plc will post -0.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AUTL has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, June 17th. William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $8.70.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.